

Literatur

- 1 Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infectious disease clinics of North America* 2014;28(1):1–13.
- 2 Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. *BMC Med* 2011;9:107.
- 3 van Nieuwkoop C, Bonten TN, van't Wout JW, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. *Critical care* 2010; 14(6):R206.
- 4 Ottiger C, Schaer G, Huber AR. Time-course of quantitative urinary leukocytes and bacteria counts during antibiotic therapy in women with symptoms of urinary tract infection. *Clin Chim Acta* 2007; 379(1–2):36–41.
- 5 Drozdov D, Thomer A, Meili M, et al. Triple P study group. Procalcitonin, pyuria and proadrenomedullin in the management of urinary tract infections – ‘triple p in uti’: study protocol for a randomized controlled trial. *Trials*. 2013;14:84.
- 6 Randazzo M, Beatrice J, Huber A, et al. A «PSA Pyramid» for Men with Initial Prostate-specific Antigen <3 ng/ml: A Plea for Individualized Prostate Cancer Screening. *Eur Urol*. 2014 Apr 18. pii: S0302-283800318-2. doi: 10.1016/j.eururo.2014.04.005.
- 7 Soverini S, Hochhaus A, Nicolini FE et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. *Blood* 2011;118: 1208–15.
- 8 Nigro N, Müller B, Morgenthaler N, et al. The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases. *Swiss Med Wkly*. 2011;141:13270.
- 9 Widmer D, Drozdov D, Rüggeger K, et al. Effectiveness of Proadrenomedullin Enhanced CURB65 Score Algorithm in Patients with Community-Acquired Pneumonia in «Real Life», an Observational Quality Control Survey. *J Clin Med* 2014;3:267–79.
- 10 Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. *Lancet*. 2014 Aug 6. pii: S0140-673660525-0. doi: 10.1016/S0140-673660525-0.
- 11 Sousa Da Silva RX, Dusemund F, Nickel C, Bingisser R, Huber A, Müller B, Albrich WC. Validation of a risk-based biomarker-enhanced scoring system for lower respiratory tract infections (OPTIMA I Basel) – An observational survey. *International Journal of Clinical Medicine* 2013;4:69–77.
- 12 Dusemund F, Steiner M, Vuilliamenet A et al. Multidisciplinary Assessment to Personalize Length of Stay in Acute Decompensated Heart Failure (OPTIMA II ADHF). *J Clin Med Res* 2012;4: 402–9.
- 13 Schuetz P, Christ-Crain M, Albrich W, Zimmerli W, Mueller B. Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: Insights into the ProHOSP study. *Virulence* 2010;1:88–92.
- 14 Winzeler BF, Christ-Crain M. Hormone als Biomarker für Diagnose und Prognose. *Praxis (Bern 1994)*. 2012;101:251–7.